$LXRX Fill The Gap And Go Or Will It Breakdown?

LXRX is a penny stock that has performed well over the last few weeks but looking at the chart, shares are trading within the gap zone. Volume this week compared to previous weeks is lower. Is that a concern or just a slow week?

"Shares of LXRX stock have been on a tear for around a month. This was ever since terminating its partnership agreement with Sanofi. The termination gave Lexicon full control over its diabetes product Zynquista and in addition to that, Sanofi is going to pay the company as much as $260 million as a parting shot...The company will be conducting poster presentations of its XERMELO therapy this week at the North American Neuroendocrine Tumor Society Annual Multidisciplinary NET Medical Symposium."*

About LXRX

Lexicon Pharmaceuticals is a biopharmaceutical company that uses mouse genetics to discover the function of genes and find promising drug targets. Lexicon then designs and develops drugs for these targets, which cover a broad spectrum of therapeutic areas. Following a restructuring in January 2014, Lexicon focused efforts on two drugs: sotagliflozin in diabetes, which is partnered with Sanofi, and Xermelo (telotristat etiprate) in carcinoid syndrome, which is partnered with Ipsen outside the U.S. Early-stage programs include SGLT1 inhibitor LX2761 and neuropathic pain drug LX9211.

*SOURCE: Are Penny Stocks Worth It? 3 Up Big In October